FDA Approves Kiniksa's Arcalyst for Recurrent Pericarditis
Kiniksa Pharmaceuticals has received FDA approval for Arcalyst (rilonacept), a once-weekly subcutaneous injection for treating recurrent pericarditis and reducing its risk of recurrence in adults and children age 12 years and older.
A recombinant-fusion protein, Arcalyst works by blocking interleukin-1 alpha and interleukin-1 beta signaling that cause inflammation leading to pericarditis, a swelling of the thin sac-like membrane encircling the heart.
Approval was supported by phase 3 trial results showing the drug had a 97 percent treatment response rate in enrollees, with patients seeing a 96 percent reduction in risk of a recurrent pericarditis event, and participants being pain-free or experiencing minimal pain 92 percent of the trial’s duration vs. 40 percent of trial days in the placebo group.
Kiniksa plans to commercially launch Arcalyst next month.
Upcoming Events
-
07May
-
14May
-
30May